Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage.
Precise and reliable detection of diseases in early stages allows prompt initiation of therapy and results in minimizing patients' burden
Explore our offer here
OCTOBER 21, 2021
By Marilynn Larkin
SOURCE: https://www.mdalert.com/news/article/urinary-peptidomic-profile-predicts...
NEW YORK (Reuters Health) - Researchers have produced and validated a urinary peptidomic profile (UPP) biomarker that distinguishes healthy from unhealthy aging based on fibrosis and extracellular matrix (ECM) remodeling in patients with chronic diseases.
A consortium of researchers belonging to the Research Institute Alliance for the Promotion of Preventive Medicine (Mechelen, Belgium), Mosaiques-Diagnostics (Hannover, Germany), Hospital, St. Georg (Leipzig, Germany), and the Universities of Hasselt and Leuven in Belgium and other European Research Institutes published today an article in The Lancet Healthy Longevity that shows data underpinning the groundbreaking idea that analysis of a small urine sample provides information on a person’s biological age and the probability of that a person will age healthy.
Symbiosis of diagnostics and therapy
Mosaiques Diagnostics & Therapeutics AG has pursued this goal through intensive research over the last 20 years and has developed a technology to transfer this vision into practice. The technology is now available to detect diseases as early as possible and with unprecedented precision. This is what makes it possible to effectively treat diseases with drug therapies at the earliest timepoint.
Mosaique's clinical proteome analysis enables:
The mosaiques diagnostics & therapeutics AG was established in Hannover (Germany).
The company’s core competence is the early and reliable detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns (DiaPat) derived from the fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid).
